Pneumonia
Pneumonia is an inflammatory lung infection affecting the alveoli and lower airways, causing symptoms such as fever, chills, difficulty breathing, fatigue, chest pain, and a cough that may be productive or dry. The severity varies, and bacterial cases are treated with antibiotics.
Health Outcomes
- Accelerated Recovery of B Cell-Mediated Respiratory Immunity
- Adverse Safety Concern from Antimicrobial Resistance
- Altered Antibiotic Susceptibility
- Blocked Pneumococcal Binding Sites
- Co-Aggregation with Pathogens
- Colonization of Nasopharynx or Adenoid Tissue
- Decreased Oxygen Saturation
- Decreased Oxygenated Hemoglobin Level
- Delayed Onset of Illness Episode
- Diagnosis of Meningitis
- Disrupted Bacterial Cell Membranes
- Efficacy of Postbiotics in Immunocompromised Patients
- Elevated Antipneumococcal IgA Levels in Bronchoalveolar Lavage Fluid
- Elevated Type I IFN Expression in Lung Lymphocytes
- Elevated Viable Bacterial Counts
- Enhanced Anti-Infective Properties
- Enhanced Antimicrobial Capacity
- Enhanced Antimicrobial Resistance
- Enhanced Antipathogenic Activity
- Enhanced Antipneumococcal IgA Levels in BAL
- Enhanced Disease Resistance
- Enhanced IgA Response
- Enhanced Immune Profile
- Enhanced Immune System
- Enhanced Immunity to Pneumococcal Infections
- Enhanced Immunological Defense Against Respiratory Viral Infections
- Enhanced Influenza Resistance
- Enhanced Innate Immune Function
- Enhanced Interferon Production
- Enhanced Non-specific Immune Defense
- Enhanced Phagocytosis by Monocyte-Derived Dendritic Cells
- Enhanced Protection Against Infection
- Enhanced Protection Against Streptococcus Pyogenes Infection
- Enhanced Pulmonary Immune Response
- Enhanced Resistance to Infections
- Enhanced Resistance to Respiratory Infections
- Enhanced Resistance to Streptococcus Pneumoniae Infection
- Enhanced Respiratory Burst Activity
- Improved Airway Secretion Clearance
- Improved Anti-infection Response
- Improved Antibiotic Resistance Outcomes
- Improved Antibiotic Sensitivity
- Improved Antibiotic Susceptibility
- Improved Antimicrobial Ability
- Improved Bacterial Survival Rate
- Improved Bacterial Viability Under Stress
- Improved Bactericidal Function of Phagocytic Cells
- Improved Chest X-Ray Finding
- Improved Clinical Symptoms of Influenza
- Improved Cure Rate on Day 3
- Improved Cure Rate on Day Four
- Improved Defense Mechanism Recovery
- Improved Disease Resolution
- Improved Histopathological Findings in Lungs
- Improved Host Health
- Improved Host Immunity
- Improved Humoral Immune Response
- Improved Immune Mechanisms Against S. pneumoniae
- Improved Immune Response
- Improved Infection Protection
- Improved Innate Immunity
- Improved Leukocyte Recruitment
- Improved Lower Limit of Detection
- Improved Lung Barrier Function
- Improved Lung Function
- Improved Lung Injury Outcomes
- Improved Mucosal Immunity
- Improved Neutrophil Function
- Improved Nonspecific Humoral Response
- Improved Overall Survival During Infection
- Improved Oxygenation Index
- Improved Pathogen Clearance
- Improved Pathogen Tolerance
- Improved Perceived Recovery
- Improved Phagocyte-mediated Bactericidal Activity
- Improved Phagocytic Activity
- Improved Pneumococcal Infection Outcomes
- Improved Recovery Rate
- Improved Relative Survival Rate Against Pathogen
- Improved Resistance Against Respiratory Syncytial Virus
- Improved Resistance against Infections
- Improved Resistance to Infections
- Improved Resistance to Pathogenic Infection
- Improved Resistance to Pneumococcal Infection
- Improved Resistance to RSV Infection
- Improved Resistance to Secondary Pneumococcal Pneumonia
- Improved Respiratory Humoral Response
- Improved Respiratory Immune Function
- Improved Respiratory Immunity
- Improved Respiratory Infection Resistance
- Improved Respiratory Mucosal Barrier Function
- Improved Respiratory Tract Health
- Improved Serum Bactericidal Activity
- Improved Serum Immunity
- Improved Serum-Mediated Pathogen Killing
- Improved Specific Antibody Response
- Improved Survival Rate After Bacterial Challenge
- Improved Survival Rate Against Infection
- Improved Survival Rate Following Infection
- Improved Symptom Resolution Rate
- Improved Vaccine-Specific Secretory IgA Levels in Saliva
- Incidence of Late-Onset Sepsis
- Increased Abundance of Antibiotic Resistance Genes
- Increased Anti-Pneumococcal Antibody Levels
- Increased Anti-Viral Factor Expression in Lung
- Increased Antibacterial Activity
- Increased Antibiotic Susceptibility
- Increased Antibiotic Use
- Increased Antibody Response
- Increased Antigen-Specific Immunoglobulin A
- Increased Antimicrobial Resistance
- Increased Antipathogen Activity Against Escherichia coli
- Increased Bacteremia
- Increased Bacteremia Incidence
- Increased Body Temperature
- Increased Days Alive and Out of Hospital
- Increased Dispersal of Pathogenic Bacteria
- Increased Economic Burden Due to Higher Antibiotic Costs
- Increased Fever
- Increased Fever-Free Days
- Increased Hospital Admissions
- Increased IL-8 Levels at 24 Hours
- Increased Infection
- Increased Inflammatory Cell Counts
- Increased Inhibition of Pathogenic Bacteria
- Increased Length
- Increased Length of Hospitalization Due to Vancomycin Resistance
- Increased Leukocyte Count
- Increased Lung CD3+CD4+ IFN-γ+ T Cells
- Increased Mortality in Patients with Enterococcal Bacteremia
- Increased Opsonophagocytic Activity
- Increased Post-Infection Lung Monocyte Levels
- Increased Resistance to Pneumococcal Infections
- Increased Respiratory Burst Activity
- Increased Risk of Sepsis
- Increased Sepsis
- Increased Sepsis Incidence
- Increased Survival Against Pathogens
- Increased Survival During Pathogenic Exposure
- Increased Tetracycline Resistance
- Increased Vaccine-Specific Plasma Immunoglobulin G (IgG)
- Induction of Antimicrobial Chemokines
- Inhibited NI1060 in Pasteurella
- Inhibition of Harmful Bacterial Growth
- Inhibition of RSV Replication
- Managed Cystic Fibrosis
- Modulated Pulmonary Innate Immune Microenvironment
- Modulated Pulmonary Innate Immune Response
- Modulation of Pulmonary Innate Immune Function
- Neutral Effect on Respiratory Infections Caused by Streptococcus Pneumoniae
- No Change in Blood-Culture Confirmed Sepsis
- No Significant Reduction in Lower Respiratory Tract Infections
- Occurrence of Necrotising Pneumonia
- Occurrence of Septic Shock
- Post-Vaccinal Immunostimulatory Effect
- Presence of Multidrug-Resistant Sepsis
- Preserved Alveolar-Capillary Barrier
- Preserved Anti-pseudomonal Activity
- Protection Against Pathogen Dissemination
- Recovered from Bacteremia without Sequelae
- Reduced Acute Kidney Injury
- Reduced Acute Respiratory Tract Infection Incidence
- Reduced Antibiotic Duration
- Reduced Antibiotic Sensitivity
- Reduced Antibiotic Usage
- Reduced Antibiotic Use Due to Infections
- Reduced Antimicrobial Use
- Reduced Bacteremia
- Reduced Bacterial Infection Severity
- Reduced Bacterial Load in Blood
- Reduced Bacterial Load in Lungs
- Reduced Beta-Lactam Resistance
- Reduced Brain Abscess Incidence
- Reduced Clinical Sepsis
- Reduced Community-Acquired Infection
- Reduced Community-Acquired Infection Incidence
- Reduced Cumulative Mortality After Infection
- Reduced Day Care Absenteeism Due to Infections
- Reduced Duration of Acute Respiratory Infection
- Reduced Duration of Antibiotic Usage
- Reduced Duration of Febrile Episodes
- Reduced Duration of Hospitalization
- Reduced Duration of Mechanical Ventilation
- Reduced Duration of Nosocomial Infections
- Reduced Duration of Respiratory Tract Infection Episode
- Reduced Duration of Respiratory Tract Infections
- Reduced Emergency Care Unit Stay Duration
- Reduced Expression of Pro-Inflammatory Cytokines in Lung
- Reduced Febrile Flares
- Reduced Fever
- Reduced Fever Days
- Reduced Fever Incidence
- Reduced GAS Adherence to Host Epithelial Cells
- Reduced Hospital Length of Stay
- Reduced Hospital Mortality Rate
- Reduced Hospital Readmission Risk
- Reduced Hospital Stay
- Reduced Hospital Stay Duration
- Reduced Hospitalisation
- Reduced Hospitalization Duration
- Reduced Hypoxia
- Reduced ICU Length of Stay
- Reduced Illness Incidence
- Reduced Impact of Gram-negative Microorganisms
- Reduced In-hospital Mortality
- Reduced Incidence of Bacterial Infections
- Reduced Incidence of Bacterial Pneumonia
- Reduced Incidence of Common Infections
- Reduced Incidence of Infections
- Reduced Incidence of Invasive Infections
- Reduced Incidence of Respiratory Illness
- Reduced Infant Infections
- Reduced Infection Incidence
- Reduced Infection Rate
- Reduced Infection Severity
- Reduced Infectious Complication
- Reduced Inflammation in the Lower Respiratory Tract
- Reduced Intensive Care Unit Mortality
- Reduced Intensive Care Unit Stay
- Reduced Length of Hospital Stay
- Reduced Length of Hospitalization
- Reduced Length of Intensive Care Unit Stay
- Reduced Length of Stay
- Reduced Lower Respiratory Infection
- Reduced Lung Histopathology Scores
- Reduced Lung Injury
- Reduced Lung Tissue Damage
- Reduced Lung Viral Proliferation
- Reduced Lung Viral Titers
- Reduced Lung Viral Titers After Influenza
- Reduced Mean Number of Infections per Child
- Reduced Mechanical Ventilation Duration
- Reduced Mold Presence
- Reduced Morbidity
- Reduced Mortality
- Reduced Mortality Post-Challenge with S. agalactiae
- Reduced Mortality Post-Infection
- Reduced Mortality Rate Before Discharge
- Reduced Mortality Rate During Pathogen Challenge
- Reduced NO Secretion Induced by LPS
- Reduced Need for Intubation or Ventilation
- Reduced Nontransferable Antibiotic Resistance
- Reduced Nosocomial Infection Rate
- Reduced Occurrence of Pasty Vent
- Reduced Opportunistic Pathogenic Bacteria Levels
- Reduced Organ Failure Severity
- Reduced Oxygen Requirement
- Reduced PICU Discharge Time
- Reduced Pathogen Activity
- Reduced Pathogen Adhesion
- Reduced Pathogen Attachment
- Reduced Pathogen Counts in Organs
- Reduced Pathogen Growth
- Reduced Pathogen Incidence
- Reduced Pathogenic Bacteria
- Reduced Pathogenic Bacterial Load In Vivo
- Reduced Pathogenic Colonies
- Reduced Pathogenic Contamination
- Reduced Peak Inspiratory Pressure
- Reduced Pediatric Intensive Care Unit Stay
- Reduced Pneumococcal Adherence
- Reduced Postinfective Symptoms
- Reduced Postoperative Infectious Complications
- Reduced Potential Pathogens
- Reduced Pseudomonas Levels
- Reduced Pseudomonas aeruginosa-Induced Damage
- Reduced Pulmonary Free-CML
- Reduced Pulmonary Inflammation
- Reduced RSV Titre in Lung
- Reduced RSV Viral Load in Lungs
- Reduced Recovery Time
- Reduced Respiratory Burst Activity
- Reduced Respiratory Illness
- Reduced Respiratory Infections in Infants
- Reduced Respiratory Pathogen Load
- Reduced Respiratory Symptoms
- Reduced Respiratory Tract Infection
- Reduced Respiratory Tract Infection Episode
- Reduced Respiratory Tract Infection Episodes
- Reduced Respiratory Tract Infections
- Reduced Risk of Antimicrobial Resistance
- Reduced Risk of Prolonged Respiratory Infections
- Reduced SOFA Score
- Reduced School Absence Days
- Reduced School Absenteeism Due to Infectious Diseases
- Reduced Sepsis Incidence
- Reduced Severity of Acute Respiratory Infection
- Reduced Severity of Lung Injuries
- Reduced Short-term Mortality
- Reduced Sick Leave Days
- Reduced Staphylococcus Aureus Infection
- Reduced Streptococcus pneumoniae in Lung
- Reduced Survival of Listeria innocua
- Reduced Symptom Duration
- Reduced Time to Symptom Resolution
- Reduced Total Cells in Bronchoalveolar Lavage Fluid
- Reduced Total Infections
- Reduced Transmission of Antibiotic-Resistant Genes
- Reduced Upper Respiratory Infections
- Reduced Virus Titers in Bronchoalveolar Lavage Fluid
- Septicemia Incidence
- Shortened Treatment Course
- Synergistic Antibiotic Effect
- White Blood Cell Count